SAVE THE DATES

We are pleased to invite you to join Medicilon at the 74th ASMS Conference (May 31 – June 4, 2026, San Diego Convention Center).

On Thursday during the poster session (10:30 am – 2:30 pm), we will present two advanced LC MS/MS methods:

Poster #ThP 042

Quantification of Antibody-Conjugated Drug in Cleavable ADCs: A Universal, Automated, and Cost-Effective LC-MS/MS Platform

Presenter: Mimi Wan – Director of DMPK, Medicilon

Poster #ThP 159

A Sensitive LC-MS Bioanalytical Method for Simultaneous Quantification of Structurally Similar Cyclic Tetrapeptides at the Picogram Level

Presenter: Wenchuan Ma – Principal Scientist I of DMPK, Medicilon

These posters reflect our broader DMPK & Bioanalysis capabilities, which span in vitro ADME, in vivo PK, MetID, Radiolabeled ADME, and bioanalysis for both traditional and emerging modalities.

Why Medicilon for your DMPK needs?

• End-to-end support – From discovery screening through IND/NDA filings
• Global footprint – Facilities in the US (Boston) and China (Shanghai)
• Regulatory expertise – IND/NDA-ready packages aligned with FDA, NMPA, and OECD standards
• Proven track record – Over 20 years of experience with 650+ IND approvals supported

Key highlights include:

• ADC bioanalysis – Conjugated/total antibody, free small molecule/metabolites, ADA
• New modalities – Peptides, PROTACs, oligonucleotides, siRNA, mRNA, cell/gene therapy
• Sensitivity – siRNA quantitation down to 1 10 ng/mL from only 20 μL plasma with excellent reproducibility over >1300 injections
• Full species – Non human primate, dog, minipig, rabbit, rat, mouse, plus specialized models for ophthalmic & inhaled drugs

Whether you are working on ADCs, cyclic peptides, or other challenging modalities, our team looks forward to discussing how we can support your DMPK programs.

Stop by our posters or reply to this email to schedule a meeting at ASMS.